查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011182

放射性药物市场：2026-2032年全球市场预测（按放射性同位素类型、製造技术、应用和最终用户划分）

Radiopharmaceuticals Market by Radioisotope Type, Production Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，放射性药物市场价值将达到 58.4 亿美元，到 2026 年将成长到 62 亿美元，到 2032 年将达到 91.9 亿美元，复合年增长率为 6.69%。

主要市场统计数据
基准年 2025 58.4亿美元
预计年份：2026年 62亿美元
预测年份 2032 91.9亿美元
复合年增长率 (%) 6.69%

对当今放射性药物市场格局进行简要概述，重点关注技术、临床需求以及影响产业决策的策略重点。

全球放射性药物产业正经历技术快速发展和策略重组的时期。同位素生产和自动化的最新创新降低了临床和研究领域众多终端使用者的操作复杂性，同时，多个治疗领域日益增长的临床需求也使得供应链韧性和合规性备受关注。随着相关人员重新评估筹资策略和资金配置，亟需进行简洁、以证据为基础且全面性的分析，将技术、临床应用和终端使用者能力整合到一个切实可行的决策架构中。

同位素生产的去中心化、治疗诊断学的进步以及监管政策的澄清，正在如何重塑放射性药物的临床应用和商业性机会？

放射性药物领域正经历一场变革，其驱动力来自治疗诊断学生产技术的创新、诊疗一体化技术的进步以及靶向临床应用证据基础的不断扩大。迴旋加速器效率的提升和小型化发生器系统的改进，使得关键同位素的取得更加分散化，让地方医院和诊断中心能够探索先前只有大规模学术机构才能实现的现场或近场生产模式。同时，先进合成模组带来的自动化正在减少人工操作时间，提高生产过程的可重复性，即使在更严格的监管要求下也能实现高通量生产。

美国2025年关税的最新进展促使放射性药物相关人员重组其供应链、将生产转移到近岸地区，并改变其库存策略。

美国将于2025年实施关税及贸易政策调整，将进一步加剧依赖跨国供应链取得放射性前驱物、设备和成品放射性药物的利害关係人的困境。进口关税和合规程序增加了从海外供应商采购专用组件的成本和行政负担，迫使许多机构重新评估其供应商基础和物流策略。为此，多家製造商和临床网路正在加速推动近岸外包和垂直整合，以降低关税变化带来的风险，并确保关键同位素和耗材供应链的持续性。

将同位素特性、生产方法、临床应用和最终用户操作实践与策略性投资选择联繫起来的实用、细分主导的见解。

细分市场层面的洞察揭示了特定细分市场的趋势，这些趋势应指南产品开发、商业化和营运投资。根据放射性同位素的类型，氟-18、镓-68、碘-131、镏-177 和Technetium-99m 各有不同的临床和物流特性，因此在生产计划、低温运输管理和监管文件方面需要考虑不同的因素。换句话说，製造商必须调整其产能和品管系统，以适应每种同位素的崩坏特性和处理限制。根据製造技术，製造方法的选择——自动化合成模组、迴旋加速器、产生器和核子反应炉——需要在资本密集度、处理能力和地理柔软性之间进行权衡。这些权衡应体现在网路设计和资本分配决策中。

美洲、欧洲、中东和非洲以及亚太地区的区域基础设施、监管多样性和临床重点如何决定准入模式和战略伙伴关係。

区域趋势影响供应方的策略选择和临床实施路径。在美洲，对先进迴旋加速器基础设施的投资以及紧密的医院和诊断中心网络，为扩大短寿命同位素的生产和试点分散式模式创造了有利环境，使用于影像和治疗的放射性核素更贴近患者。另一方面，区域监管协调和报销方案的差异要求采取个人化的市场准入策略，并且需要与当地保险公司密切合作才能确保成功实施。

塑造该行业的竞争策略包括垂直整合、与医疗诊断治疗诊断学合作、投资自动化以及扩大契约製造。

产业领导者正透过垂直整合、策略伙伴关係以及对自动化和品管系统的重点投资来实现差异化竞争。一些企业正在投资建造模组化和扩充性的生产设施，以支援分散式供应链模式；而其他企业则寻求与製药研发公司合作，共同开发治疗诊断学化合物和伴随诊断试剂。同时，合约研发生产（CDMO）服务商也在拓展服务范围，将灌装包装、放射性标记和供应链管理服务纳入其中，以应对小规模生物技术创新者和成熟製造商所面临的特定挑战。

为放射性药物领域的产业领导者提供切实可行的、重点突出的策略措施，以加强供应链、加速临床部署并确保竞争优势。

产业领导者应优先采取一系列切实可行且影响深远的措施，以增强韧性和商业性潜力。首先，他们应加快对生产基地的评估，重点关注模组化、扩充性的资产，以支援短半衰期同位素的分散式供应，并在能够降低变异性和劳动密集度的领域整合自动化。其次，他们应寻求选择性的近岸外包和区域伙伴关係，以降低关税风险并缩短物流路线，同时与多家供应商签订关键前体和耗材的合同，以降低单一来源风险。

我们透过透明且可重复的研究过程，结合专家访谈、技术检验和文献整合，为放射性药物提供实用见解。

本执行摘要依据的研究整合了一级资讯来源和二级资讯来源，在保持方法论透明度的同时，提供了基于证据的观点。一级资讯来源包括对生产经理、临床经理和供应链经理的结构化访谈，以及与迴旋加速器运作、产生器技术和自动化合成领域专家的技术咨询。二级资讯来源包括监管指南、同侪审查的临床文献以及生产设施的营运数据，这些数据用于评估产量、品质系统和物流实践。

结论强调韧性、实证采纳和策略能力建构是放射性药物领域未来成功的决定因素。

总之，放射性药物产业正朝着更分散化、实证化和以品质为中心的模式发展。生产技术和自动化的进步推动了製造地的多元化，而治疗诊断学的发展则为临床和商业性合作开闢了新的途径。同时，政策变革和贸易措施促使人们重新评估供应链设计和筹资策略，凸显了韧性和营运柔软性的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：放射性同位素放射性药物市场

  • 氟-18
  • 镓-68
  • 碘-131
  • 镏-177
  • Technetium-99m

第九章：依生产技术分類的放射性药物市场

  • 自动合成模组
  • 迴旋加速器系统
  • 生成器方法
  • 核子反应炉基地

第十章：放射性药物市场：依应用领域划分

  • 循环系统
  • 内分泌学
  • 神经病学
  • 肿瘤学

第十一章：放射性药物市场：依最终用户划分

  • 诊所
  • 诊断中心
  • 医院
  • 研究机构

第十二章：放射性药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：放射性药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：放射性药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国放射性药物市场

第十六章：中国放射性药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Accelerator Applications
  • Bayer AG
  • Bracco Imaging SpA
  • Cardinal Health Inc.
  • Curium Pharma
  • Eli Lilly and Company
  • Fusion Pharmaceuticals Inc.
  • GE Healthcare
  • IBA Molecular
  • ImaginAb Inc.
  • Jubilant Pharma Limited
  • Lantheus Holdings Inc.
  • Norgine BV
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • NuView Life Sciences
  • Pharmalogic LLC
  • Positron Corporation
  • RadioMedix Inc.
  • Telix Pharmaceuticals Limited
  • Theragnix Technologies LLC
  • Zevacor Pharma Inc.
Product Code: MRR-4308E1C887A3

The Radiopharmaceuticals Market was valued at USD 5.84 billion in 2025 and is projected to grow to USD 6.20 billion in 2026, with a CAGR of 6.69%, reaching USD 9.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.84 billion
Estimated Year [2026] USD 6.20 billion
Forecast Year [2032] USD 9.19 billion
CAGR (%) 6.69%

A succinct orientation to today's radiopharmaceutical environment highlighting technology, clinical demand, and strategic priorities shaping industry decisions

The global radiopharmaceutical landscape is undergoing a period of accelerated technological evolution and strategic repositioning. Recent innovations in isotope production and automation have reduced complexity for many clinical and research end users, while rising clinical demand across multiple therapeutic areas has intensified attention on supply chain resilience and regulatory alignment. As industry stakeholders reassess procurement strategies and capital allocation, they require concise, evidence-based synthesis that links technology, clinical application, and end-user capacity to practical decision frameworks.

This executive summary synthesizes complex developments into actionable insight, emphasizing how production modalities, isotope diversity, and application-specific dynamics converge to shape operational priorities. It frames the major trends influencing investment, partnerships, and commercialization, while clarifying implications for manufacturers, clinical service providers, and policy makers. By focusing on structural drivers rather than speculative projections, the introduction grounds subsequent analysis in observable shifts in technology adoption, regulatory posture, and clinical demand patterns. Consequently, readers will gain a clear starting point for evaluating where to focus strategic effort in the near and medium term.

How decentralization of isotope production, theranostics momentum, and regulatory clarity are reshaping clinical access and commercial opportunity for radiopharmaceuticals

The radiopharmaceutical sector is experiencing transformative shifts driven by innovation in radioisotope production, advances in theranostics, and an expanding evidence base for targeted clinical applications. Developments in cyclotron efficiency and compact generator systems are decentralizing access to key isotopes, enabling community hospitals and diagnostic centers to contemplate onsite or near-site production models where previously only large academic centers could participate. At the same time, automation through advanced synthesis modules is reducing hands-on time, improving reproducibility, and enabling higher throughput under tighter regulatory requirements.

Theranostic approaches have elevated the commercial and clinical value of certain radionuclides, prompting strategic partnerships between molecular imaging companies, pharmaceutical developers, and contract manufacturers. This convergence is further supported by expanding clinical trials in oncology and neurology, which are generating robust datasets that inform reimbursement discussions and clinical adoption. Additionally, regulatory authorities are increasingly issuing guidance that clarifies manufacturing quality expectations for novel radioligands, thereby lowering barriers to scale when sponsors can meet these standards. Overall, the landscape is moving toward a more distributed yet quality-focused ecosystem, where agility, manufacturing reliability, and clinical evidence become decisive competitive differentiators.

How recent United States tariff developments in 2025 are prompting supply chain reconfiguration, nearshoring, and inventory strategy changes across radiopharmaceutical stakeholders

The introduction of tariffs and trade policy shifts in the United States in 2025 has introduced an additional layer of complexity for stakeholders that depend on cross-border supply chains for precursors, equipment, and finished radiopharmaceuticals. Import duties and compliance processes have increased the cost and administrative burden associated with sourcing specialized components from international suppliers, which has prompted many organizations to reevaluate their supplier base and logistics strategies. In response, several manufacturers and clinical networks have accelerated nearshoring and vertical integration efforts to reduce exposure to tariff volatility and to secure continuity of supply for critical isotopes and consumables.

Meanwhile, transitional frictions in customs clearance and increased scrutiny of product classification have lengthened lead times for certain imported goods, encouraging greater inventory buffers and contractual contingencies. As a result, procurement teams are placing greater emphasis on validated domestic supply options, multi-sourcing strategies, and the development of in-region manufacturing capabilities. These adjustments, in turn, influence capital planning, site selection for production assets, and decisions regarding strategic stockpiles. In sum, the tariff environment has catalyzed a rethink of supply chain robustness, compelling organizations to balance cost pressures with the imperative of uninterrupted clinical delivery.

Actionable segmentation-driven insights linking isotope characteristics, production modalities, clinical applications, and end-user operating realities to strategic investment choices

Segment-level intelligence reveals differentiated dynamics that should guide product development, commercialization, and operational investments. Based on Radioisotope Type, the clinical and logistical profiles of Fluorine-18, Gallium-68, Iodine-131, Lutetium-177, and Technetium-99m each present distinct considerations for production scheduling, cold chain management, and regulatory documentation, which means manufacturers must align capacity and quality systems to the decay characteristics andhandling constraints of each isotope. Based on Production Technology, choices between Automated Synthesis Modules, Cyclotron Based, Generator Based, and Reactor Based production create trade-offs between capital intensity, throughput, and geographic flexibility, and these trade-offs should inform network design and capital allocation decisions.

Based on Application, the clinical pathways and reimbursement trajectories vary significantly across Cardiology, Endocrinology, Neurology, and Oncology, so commercial teams must tailor evidence generation and payer engagement strategies to the clinical value propositions relevant to each specialty. Based on End User, operational and service models differ between Clinics, Diagnostic Centres, Hospitals, and Research Institutes, affecting demand patterns, procurement lead times, and the types of service agreements that will be most compelling. Taken together, these segmentation lenses enable organizations to prioritize investments in production technology and clinical evidence according to the intersection of isotope attributes, manufacturing capabilities, therapeutic use cases, and end-user operating realities. Consequently, segmentation-driven strategies will be central to achieving operational efficiency and commercial traction.

How regional infrastructure, regulatory diversity, and clinical priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific determine access models and strategic partnerships

Regional dynamics shape both supply-side strategic choices and the pathways for clinical adoption. In the Americas, investment in advanced cyclotron infrastructure and a dense network of hospitals and diagnostic centers create a favorable environment for scaling production of short-lived isotopes and for piloting decentralized models that bring imaging and therapeutic radionuclides closer to patients. Conversely, regulatory harmonization and reimbursement variability across jurisdictions require tailored market-entry approaches and close engagement with regional payers to secure adoption.

In Europe, Middle East & Africa, diverse regulatory regimes and variable access to capital mean that partnerships and contract manufacturing arrangements are often the most efficient route to expand clinical availability, while regional hubs with reactor or cyclotron capacity continue to supply neighboring markets. Many countries in this region are actively investing in capability building, which opens opportunities for technology transfer and training programs. In the Asia-Pacific region, rapid expansion of clinical imaging infrastructure and strong government support for biotechnology have accelerated local production capabilities and interest in theranostic agents, yet fragmented regulatory pathways and differing clinical practice patterns require nuanced market access strategies. Across regions, cross-border collaboration, supply chain redundancy, and targeted clinical evidence programs remain essential to manage operational risk and to accelerate patient access.

Competitive strategies shaping the sector including vertical integration, partnerships for theranostics, automation investments, and contract manufacturing expansion

Leading industry participants are differentiating themselves through a combination of vertical integration, strategic partnerships, and focused investments in automation and quality systems. Some organizations are investing in modular, scalable production assets to support decentralized delivery models, while others pursue collaborations with pharmaceutical developers to co-develop theranostic compounds and companion diagnostics. In parallel, contract development and manufacturing providers are expanding service portfolios to include fill-finish, radiolabeling, and supply chain management services that address specific pain points for both small biotech innovators and established manufacturers.

Strategic M&A and licensing arrangements are also reshaping competitive positioning, enabling faster access to new isotopes, intellectual property, and distribution networks without the lead time associated with greenfield production. Equally important, companies that invest early in automation of synthesis modules and in robust quality-by-design approaches are achieving greater reproducibility and regulatory readiness, which can shorten time-to-market for novel radioligands. Finally, alliances with clinical networks and academic centers support evidence generation while providing pathways for real-world performance data that inform reimbursement and guideline inclusion decisions. Collectively, these company-level tactics illustrate how operational capability, strategic partnerships, and evidence generation are being used to build defensible market positions.

A focused set of practical strategic moves for industry leaders to fortify supply chains, accelerate clinical adoption, and secure competitive advantage in radiopharmaceuticals

Industry leaders should prioritize a set of practical, high-impact actions to strengthen resilience and commercial potential. First, accelerate evaluation of production footprints with an emphasis on modular, scalable assets that support decentralized delivery for short-lived isotopes, integrating automation where it reduces variability and labor intensity. Second, pursue selective nearshoring or regional partnerships to mitigate tariff exposure and to shorten logistical pathways, while also establishing multi-sourcing agreements for critical precursors and consumables to reduce single-source risk.

Third, align clinical evidence generation with payer expectations by designing trials and real-world evidence programs that demonstrate clear clinical utility in Cardiology, Endocrinology, Neurology, and Oncology, investing in health economic models that translate clinical outcomes into value propositions for payers. Fourth, deepen collaborations with hospitals, diagnostic centres, clinics, and research institutes to pilot service models and to gather implementation data that improves uptake. Finally, strengthen regulatory and quality frameworks early in development to ensure readiness for diverse market requirements, and invest in workforce training to support operational resilience. Taken together, these actions will help organizations convert market insight into durable operational and commercial advantage.

Transparent and reproducible research processes combining expert interviews, technical validation, and literature synthesis to deliver actionable radiopharmaceutical insights

The research underpinning this executive summary synthesizes primary and secondary sources to deliver an evidence-based perspective while maintaining methodological transparency. Primary inputs include structured interviews with manufacturing leaders, clinical directors, and supply chain managers, as well as technical consultations with experts in cyclotron operations, generator technology, and automated synthesis. Secondary sources include regulatory guidance, peer-reviewed clinical literature, and operational data from production facilities that inform assessments of throughput, quality systems, and logistics practices.

Analytical methods employed qualitative triangulation to reconcile differing stakeholder perspectives and technical validation to ensure consistency with known decay and handling constraints for each isotope. Where appropriate, case examples were used to illustrate operational approaches without extrapolating into specific market sizing or forecasting. Throughout the research process, emphasis was placed on reproducibility and practical relevance, and findings were reviewed by independent subject-matter experts to ensure that conclusions reflect current technological capabilities, regulatory trends, and observable shifts in clinical adoption.

Concluding synthesis emphasizing resilience, evidence-driven adoption, and strategic capability building as the decisive factors for future success in radiopharmaceuticals

In conclusion, the radiopharmaceutical sector is evolving toward a more distributed, evidence-driven, and quality-centric model. Advances in production technologies and automation are enabling a diversification of manufacturing footprints, while the growth of theranostics is creating new pathways for clinical and commercial collaboration. At the same time, policy changes and trade measures are prompting a re-evaluation of supply chain design and procurement strategies, underscoring the importance of resilience and operational flexibility.

For decision-makers, the implications are clear: invest in adaptable production capabilities, prioritize emission of high-quality clinical evidence tailored to specific therapeutic areas, and cultivate regional partnerships that mitigate logistical and regulatory friction. By doing so, organizations can not only manage near-term disruptions but also position themselves to capture long-term clinical and commercial opportunities as the radiopharmaceutical ecosystem matures. These choices will materially influence the pace at which new diagnostics and therapeutics reach patients and will determine which organizations lead in an increasingly complex and competitive environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiopharmaceuticals Market, by Radioisotope Type

  • 8.1. Fluorine-18
  • 8.2. Gallium-68
  • 8.3. Iodine-131
  • 8.4. Lutetium-177
  • 8.5. Technetium-99m

9. Radiopharmaceuticals Market, by Production Technology

  • 9.1. Automated Synthesis Modules
  • 9.2. Cyclotron Based
  • 9.3. Generator Based
  • 9.4. Reactor Based

10. Radiopharmaceuticals Market, by Application

  • 10.1. Cardiology
  • 10.2. Endocrinology
  • 10.3. Neurology
  • 10.4. Oncology

11. Radiopharmaceuticals Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Centres
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Radiopharmaceuticals Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Radiopharmaceuticals Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Radiopharmaceuticals Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Radiopharmaceuticals Market

16. China Radiopharmaceuticals Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Accelerator Applications
  • 17.6. Bayer AG
  • 17.7. Bracco Imaging S.p.A.
  • 17.8. Cardinal Health Inc.
  • 17.9. Curium Pharma
  • 17.10. Eli Lilly and Company
  • 17.11. Fusion Pharmaceuticals Inc.
  • 17.12. GE Healthcare
  • 17.13. IBA Molecular
  • 17.14. ImaginAb Inc.
  • 17.15. Jubilant Pharma Limited
  • 17.16. Lantheus Holdings Inc.
  • 17.17. Norgine BV
  • 17.18. NorthStar Medical Radioisotopes LLC
  • 17.19. Novartis AG
  • 17.20. NuView Life Sciences
  • 17.21. Pharmalogic LLC
  • 17.22. Positron Corporation
  • 17.23. RadioMedix Inc.
  • 17.24. Telix Pharmaceuticals Limited
  • 17.25. Theragnix Technologies LLC
  • 17.26. Zevacor Pharma Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY AUTOMATED SYNTHESIS MODULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REACTOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC CENTRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)